LT3660509T - Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti - Google Patents
Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatytiInfo
- Publication number
- LT3660509T LT3660509T LTEP19151282.1T LT19151282T LT3660509T LT 3660509 T LT3660509 T LT 3660509T LT 19151282 T LT19151282 T LT 19151282T LT 3660509 T LT3660509 T LT 3660509T
- Authority
- LT
- Lithuania
- Prior art keywords
- cell
- determining
- based method
- toxin activity
- botulin toxin
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title 1
- 230000007888 toxin activity Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1246—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Rickettsiales (O)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/42—Poisoning, e.g. from bites or stings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/709—Toxin induced
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180150997A KR101940500B1 (ko) | 2018-11-29 | 2018-11-29 | 보툴리눔 독소 활성을 결정하기 위한 세포주 및 이를 이용한 활성 결정 방법 |
| KR1020180150640A KR101983216B1 (ko) | 2018-11-29 | 2018-11-29 | 보툴리눔 독소 활성을 결정하기 위한 항체, 및 이를 이용한 활성 측정방법 |
| KR1020180159701A KR102251096B1 (ko) | 2018-12-12 | 2018-12-12 | 보툴리눔 독소 활성을 결정하는 세포 기반 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3660509T true LT3660509T (lt) | 2022-05-10 |
Family
ID=65243304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP19151282.1T LT3660509T (lt) | 2018-11-29 | 2019-01-10 | Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US10823725B2 (lt) |
| EP (2) | EP3825689A3 (lt) |
| CN (4) | CN118745222A (lt) |
| AU (2) | AU2019388130B2 (lt) |
| BR (1) | BR112021010306A2 (lt) |
| CA (1) | CA3119962A1 (lt) |
| LT (1) | LT3660509T (lt) |
| MX (1) | MX2021005902A (lt) |
| WO (1) | WO2020111449A1 (lt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220010355A1 (en) * | 2020-07-10 | 2022-01-13 | Galderma Holding SA | Cell based method for determination of botulinum toxin potency based on western blotting |
| KR102673723B1 (ko) * | 2021-05-25 | 2024-06-11 | 휴젤(주) | 신경독소 역가 측정용 신규한 신경세포주 |
| WO2023205355A1 (en) * | 2022-04-21 | 2023-10-26 | Biomadison, Inc. | Cell based assays for botulinum neurotoxin |
| CN114702600B (zh) * | 2022-06-08 | 2022-08-23 | 北京大学人民医院 | SNAP25蛋白Ser187位点磷酸化抑制剂的用途 |
| US12282755B2 (en) | 2022-09-10 | 2025-04-22 | Nikolas Louis Ciminelli | Generation of user interfaces from free text |
| CN117497037B (zh) * | 2023-11-17 | 2024-08-16 | 上海倍谙基生物科技有限公司 | 一种基于广义线性模型的培养基组分敏感性分析方法 |
| CN117887797B (zh) * | 2023-12-27 | 2024-09-20 | 中国食品药品检定研究院 | 一种梭状芽胞杆菌神经毒素效价检测方法 |
| CN119023975B (zh) * | 2024-10-31 | 2025-04-08 | 兰州生物技术开发有限公司 | 一种测定肉毒毒素活性或snap25的方法、检测产品及抗体 |
| CN119039432B (zh) * | 2024-10-31 | 2025-01-28 | 兰州生物技术开发有限公司 | 一种检测肉毒毒素活性或突触体相关蛋白的方法和试剂盒 |
| CN119044509B (zh) * | 2024-10-31 | 2025-01-28 | 兰州生物技术开发有限公司 | 测定肉毒毒素活性或突触体相关蛋白的检测产品及方法 |
| CN119462913B (zh) * | 2025-01-14 | 2025-04-08 | 中国人民解放军军事科学院军事医学研究院 | 长效中和a型肉毒毒素的抗体及用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
| US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
| DK0758900T3 (da) | 1994-05-09 | 2002-07-29 | William J Binder | Botulinumtoksin til reduktion af migræne-hovedpinesmerter |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
| EP1502601B2 (en) | 1997-07-15 | 2010-07-21 | The Regents of the University of Colorado | Use of neurotoxin therapy for treatment of urinary retention |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| CA2329523A1 (en) * | 1998-07-03 | 2000-01-13 | Innogenetics N.V. | Differential diagnosis of neurodegeneration |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| AU1706400A (en) | 1998-10-27 | 2000-05-15 | Mayo Foundation For Medical Education And Research | Methods for enhancing wound healing |
| GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
| US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
| US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
| US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
| US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
| ES2312651T3 (es) | 2001-07-27 | 2009-03-01 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Toxina botulinum en el tratamiento o prevencion del acne. |
| US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
| KR20040094756A (ko) | 2002-03-01 | 2004-11-10 | 엘란 파마슈티칼스, 인크. | 신경 포착 증후군의 치료 방법 |
| CA2558758C (en) | 2004-02-24 | 2015-06-23 | Allergan, Inc. | Botulinum toxin screening assays |
| SI3031825T1 (sl) | 2008-03-14 | 2019-12-31 | Allergan, Inc. | Preizkusi aktivnosti serotipa A botulin toksina na podlagi imunosti |
| KR101604515B1 (ko) | 2008-03-14 | 2016-03-17 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 a 활성 검정 |
| KR102017327B1 (ko) | 2009-03-13 | 2019-09-03 | 알러간, 인코포레이티드 | 면역 기반 보툴리눔 독소 혈청형 a 활성 검정에 유용한 세포 |
| WO2011036812A1 (ja) | 2009-09-28 | 2011-03-31 | 株式会社 東芝 | アリルハイドロカーボンレセプター転写活性化量を測定するための細胞、方法およびアッセイキット |
| EP3279335B1 (en) | 2011-12-31 | 2021-03-10 | Allergan, Inc. | Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-a |
| EP3014267B1 (en) | 2013-06-28 | 2018-11-07 | Merz Pharma GmbH & Co. KGaA | Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells |
| EP3270162B2 (en) | 2013-08-09 | 2023-08-16 | BioMadison, Inc. | Botulinum toxin assay with improved sensitivity |
| AU2015287964A1 (en) | 2014-07-07 | 2017-02-16 | Allergan, Inc. | Method of detecting cleaved SNAP25 in tissue samples |
| CA2954504A1 (en) | 2014-07-07 | 2016-01-14 | Allergan, Inc. | Method of detecting cleaved snap25 in tissue samples |
| EP3233911B1 (en) | 2014-12-19 | 2020-10-14 | Merz Pharma GmbH & Co. KGaA | Means and methods for the determination of the biological activity of bont/e in cells |
| WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
| KR101983216B1 (ko) * | 2018-11-29 | 2019-05-29 | 주식회사 에이비바이오 | 보툴리눔 독소 활성을 결정하기 위한 항체, 및 이를 이용한 활성 측정방법 |
| KR101940500B1 (ko) * | 2018-11-29 | 2019-01-21 | 주식회사 에이비바이오 | 보툴리눔 독소 활성을 결정하기 위한 세포주 및 이를 이용한 활성 결정 방법 |
-
2019
- 2019-01-10 LT LTEP19151282.1T patent/LT3660509T/lt unknown
- 2019-01-10 EP EP20211597.8A patent/EP3825689A3/en active Pending
- 2019-01-10 EP EP19151282.1A patent/EP3660509B1/en active Active
- 2019-01-11 US US16/245,415 patent/US10823725B2/en active Active
- 2019-08-19 CN CN202410984771.2A patent/CN118745222A/zh active Pending
- 2019-08-19 CN CN201980090838.5A patent/CN114072673B/zh active Active
- 2019-08-19 AU AU2019388130A patent/AU2019388130B2/en active Active
- 2019-08-19 BR BR112021010306A patent/BR112021010306A2/pt unknown
- 2019-08-19 CN CN202210007041.8A patent/CN114540304B/zh active Active
- 2019-08-19 CN CN202410984767.6A patent/CN118754976A/zh active Pending
- 2019-08-19 CA CA3119962A patent/CA3119962A1/en active Pending
- 2019-08-19 WO PCT/KR2019/010467 patent/WO2020111449A1/ko not_active Ceased
- 2019-08-19 MX MX2021005902A patent/MX2021005902A/es unknown
-
2020
- 2020-05-12 US US15/930,100 patent/US11169144B2/en active Active
- 2020-05-12 US US15/930,066 patent/US10908148B2/en active Active
- 2020-05-12 US US15/930,049 patent/US10866232B2/en active Active
- 2020-09-23 US US17/029,892 patent/US11360081B2/en active Active
-
2021
- 2021-09-22 US US17/482,035 patent/US20220003752A1/en not_active Abandoned
-
2023
- 2023-11-06 US US18/502,728 patent/US20240077470A1/en not_active Abandoned
-
2024
- 2024-10-24 US US18/926,247 patent/US20250044281A1/en active Pending
-
2025
- 2025-09-12 AU AU2025230774A patent/AU2025230774A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019388130A1 (en) | 2021-06-10 |
| EP3660509A1 (en) | 2020-06-03 |
| EP3825689A2 (en) | 2021-05-26 |
| US20220003752A1 (en) | 2022-01-06 |
| US20200173986A1 (en) | 2020-06-04 |
| US20200340978A1 (en) | 2020-10-29 |
| AU2019388130B2 (en) | 2025-07-10 |
| WO2020111449A1 (ko) | 2020-06-04 |
| AU2025230774A1 (en) | 2025-10-02 |
| US10866232B2 (en) | 2020-12-15 |
| CN114540304A (zh) | 2022-05-27 |
| BR112021010306A2 (pt) | 2021-11-16 |
| CN114072673B (zh) | 2024-07-26 |
| US11360081B2 (en) | 2022-06-14 |
| CA3119962A1 (en) | 2020-06-04 |
| US20210063383A1 (en) | 2021-03-04 |
| CN114072673A (zh) | 2022-02-18 |
| US10823725B2 (en) | 2020-11-03 |
| EP3660509B1 (en) | 2022-03-09 |
| US20200340979A1 (en) | 2020-10-29 |
| MX2021005902A (es) | 2021-06-23 |
| EP3825689A3 (en) | 2021-09-15 |
| US20250044281A1 (en) | 2025-02-06 |
| US20200333325A1 (en) | 2020-10-22 |
| US20240077470A1 (en) | 2024-03-07 |
| US10908148B2 (en) | 2021-02-02 |
| US11169144B2 (en) | 2021-11-09 |
| CN118745222A (zh) | 2024-10-08 |
| CN114540304B (zh) | 2025-11-18 |
| CN118754976A (zh) | 2024-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3660509T (lt) | Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti | |
| IL283845A (en) | Methods for detecting disease using analysis of rna | |
| EP3969834A4 (en) | ANTI-DRONE SYSTEM | |
| DK3548652T3 (da) | Fremgangsmåder til proteinanalyse | |
| IL291166A (en) | A method for identifying biomarkers | |
| EP4037552A4 (en) | ANALYTE MEASUREMENT SYSTEM | |
| PL4227023T3 (pl) | Metoda otrzymywania efektywnych kosztowo elementów o złożonej geometrii | |
| IL314245A (en) | Methods for object detection | |
| EP3761849A4 (en) | Method of detecting and/or predicting seizures | |
| EP3879261A4 (en) | POTENTIOMETRIC BIOSENSOR AND DETECTION METHODS | |
| EP4226656A4 (en) | AUTOMATED GUEST ACTIVITY DETECTION | |
| EP3273249A4 (en) | Analyte measurement system and tray-identifying information search method | |
| EP3610684A4 (en) | SYSTEM AND METHOD FOR DETERMINING THE COLLABORATIVE POSITION | |
| IL283007A (en) | Cell culture system and method | |
| PL3826090T3 (pl) | System i metoda wykrywania niewyrównania elektrod | |
| IL287458A (en) | Methods and systems for microsatellite analysis | |
| IL259472B (en) | An anomaly detection system and method | |
| EP3884177C0 (en) | DETECTION DEVICE FOR BEARINGS | |
| EP4042127A4 (en) | LEAK DETECTION SYSTEM | |
| EP3802885A4 (en) | DETECTION PROCEDURE | |
| DK4168581T3 (da) | Avanceret håndvægts-pcr til isomir-detektion | |
| KR102272812B9 (ko) | 생체분자 분석용 나노 플라즈모닉 센서, 키트 및 이를 이용한 생체분자 분석 방법 | |
| DK3717659T3 (da) | Fremgangsmåde til at bestemme mikrobiel følsomhed over for antibiotiske midler | |
| KR102358418B9 (ko) | 스몰 rna 검출 방법 | |
| HUE055897T2 (hu) | Eljárás C. perfringens által okozott betegségek detektálására állatokban |